Twenty U.S. states join generic drug price-fixing lawsuit

1 Attorneys

#1 Attorneys Network

1 Legal - 1 Lawyers - 1 Attorneys

Injury Lawyer - Criminal - Foreclosure - Divorce

 

By Diane Bartz | WASHINGTON

WASHINGTON California, Illinois and 18 more
states have joined a lawsuit filed last year alleging that six
companies, including Mylan NV and Teva Pharmaceutical
Industries Ltd, conspired to push up prices of two
generic drugs, the Connecticut attorney general’s office said on
Wednesday.

Connecticut, which leads the group, and 19 other states
filed the original lawsuit on Dec. 15. It added the additional
states in filing an amended complaint which also added
violations of state antitrust laws, the Connecticut attorney
general’s office said in a statement.

The state lawsuit is part of a broader effort by the federal
government, states and the U.S. Congress to address the rising
cost of many generic drugs.

The drugs involved in the state lawsuit are the delayed
release version of a common antibiotic, doxycycline hyclate, and
glyburide, an older drug used to treat diabetes.

The lawsuit, filed in the U.S. District Court for the
District of Connecticut, also names Australian drugmaker Mayne
Pharma Group Ltd, Heritage Pharmaceuticals Inc, Aurobindo Pharma
Ltd and Citron Pharma LLC.

The lawsuit characterized Heritage as the “principal
architect and ringleader” that helped organize a “wide-ranging
series of conspiracies” to fix prices. The U.S. Justice
Department filed a related lawsuit in December against two
former Heritage executives.

A spokeswoman for Aurobindo declined to comment while the
other companies did not immediately respond to requests for
comment.



1 Attorneys
1 Attorneys

1 Legal

#1 Attorneys Search Engine

1 Legal is part of the 1 Search Project

Practice Areas - News - Federal - State - Contact Us


Facebooktwitterredditpinterestlinkedinmail

Facebooktwitterlinkedinrss

1 Attorneys

#1 Attorneys Network

1 Legal - 1 Lawyers - 1 Attorneys

Injury Lawyer - Criminal - Foreclosure - Divorce

 


Leave a Reply